National authorities, regulators, industry leaders and key stakeholders gathered in London this week to discuss how to improve patient access to safe medicines with an effective pharmacovigilance framework. This 11th edition of the Medicines for Europe pharmacovigilance conference highlighted the need to engage effectively with patients and making sure the information is communicated in a clear and real-time matter. As modern technology advances, industry and regulators have an unprecedented opportunity to include patients in pharmacovigilance activities, a key element of patient involvement.
When ensuring pharmacovigilance systems remain effective, it is crucial to think not only of the operational aspects but also that every effort should be made to ensure that systems are sustainable. The 11th Pharmacovigilance conference dedicated sessions to the future of our current systems, in addressing issues such as enhancement of the Eudravigilance database, audits and inspection practices that need rethinking and how to maximise the use of electronic reporting, and minimise waste and overlap in the system.
Adrian van den Hoven, Medicines for Europe Director General commented: “Efficient pharmacovigilance is paramount to ensuring the safe use of medicines. Industry and regulators have a shared responsibility to ensure that this system remains effective and efficient. Together, we can reduce waste in the system, improve operational efficiency, prioritise and focus on processes which bring the highest benefits to patients. We commend the regulatory community on the close cooperation in the implementation the enhanced Eudravigilance and look forward to developing a clear roadmap to focus on the highest risks for patients while reducing the overload of non-essential data that the system currently generates.”
Geneva, 18 January 2018 – Today, the AMR Industry Alliance launches its first report that shows the commitment of the life sciences industry to tackle the public health threat of antimicrobial resistance (AMR). The Alliance brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries. The report was compiled by the consultancy SustainAbility. The data and case studies collected in the Alliance report provide unique insights into the practical steps members are taking to respond to AMR in the areas of research and science, access, appropriate use, and the environment. The report presents data on AMR-relevant products, including therapeutic agents or technologies that have the potential to treat or prevent infectious diseases and/or combat resistance, including but not limited to antibiotics, vaccines, diagnostics, and novel approaches to address AMR. The Alliance showcases industry’s efforts and commitment to fulfil its role as a necessary and constructive partner in finding sustainable solutions to tackle AMR.
Today, an estimated 700,000 people die each year because of the growing number of potentially deadly infectious pathogens. These include pathogens that cause tuberculosis, HIV, malaria, and staph infections, which have developed resistance to treatment regimens. AMR has the potential to turn back the clock on modern medicine. In response to this public health threat and its social and economic consequences, the United Nations in 2016 called for concerted action from governments and various sectors to address the implications of AMR. The AMR Industry Alliance is the life sciences industry’s response to this call for action.
“This first report is ground-breaking for several reasons,” explains Thomas Cueni, chair of the Alliance. “It is unique in that the companies have committed to walk the talk together and report on their progress. It is the first industry-wide grouping of this scale that has been set up to respond to the AMR emergency.”
Adrian van den Hoven, Director General, Medicines for Europe commented “The AMR Industry Alliance report is a key milestone in cementing industry commitment to tackling this global challenge in a collaborative manner. In fighting AMR, the right balance should be found between facilitating access while ensuring appropriate use. This can only be achieved by multiple stakeholders working together to define the principles of appropriate use, which ensures that public health remains safe-guarded. Patients who need antibiotic medicines should be able to have access to the appropriate treatment they need to get better. Equally, medical professionals need to be able to choose from a wide range of antibiotics to provide optimal treatment for their patients. The AMR Industry Alliance, and Medicines for Europe as member, is committed to being part of this dialogue, and taking action which we hope will change the tide on AMR.”
This first progress report has aggregated data from 36 companies from all four categories represented in the Alliance: all research-based biopharmaceutical companies (11 out of 11), half of the generics (3 out of 6), one third of diagnostics members (5 out of 15), and one quarter (17 out of 68) of SMEs provided input. The Alliance is committed to reporting progress every two years. It is also dedicated to refining its approach to better address the challenges for its members in responding, so that it can achieve greater participation than seen in this first report.
The submitted data provides considerable insight into private sector efforts to curb AMR and shows that “broadly the Alliance membership is already active and making positive contributions to the challenge of AMR, even though there is a long way to go – on full Alliance participation and greater gains against AMR,” said Denise Delaney, Director at SustainAbility.
Research and science: The report confirms a broad commitment to research by companies in 2016. At least USD 2 billion in R&D was dedicated to AMR-related products in 2016. This is a conservative number as it corresponds to the data provided by only 22 companies. These investments cover R&D-related costs for early-stage R&D exploring new product classes, ten antibiotics in late-stage clinical development, 13 clinical bacterial vaccine candidates, and 18 AMR-relevant diagnostic products, as well as other preventive therapies. A majority of Alliance companies viewed R&D incentives as either “promising but with far to go” or “insufficient relative to the challenge.”
Access: While vast amounts of antimicrobials, especially antibiotics, go to waste on patients and animals who do not need them, almost six million people die each year from infections, because they lack access to these medicines. The Alliance supports protecting the efficacy of antibiotics and making them available, where necessary, to every human being. More than two out of three Alliance companies surveyed with marketed AMR products have strategies, policies or plans in place, which include principles or efforts to improve access to their AMR-relevant products. A similar number of companies are engaged in dialogue with external stakeholders on improving access to their AMR relevant products. Many of the Alliance generics and R&D-based biopharmaceutical companies with AMR-relevant products believe more work is needed to determine how to balance expanding access with appropriate use, reduce falsified products, and work with other stakeholders to address access issues in low and middle income countries.
Appropriate use: Over 80% of all responding companies are engaged in activities to support appropriate use, while nearly half of the responding companies have a formal appropriate use strategy in place. Nearly 90% of responding companies – and 70% of those with AMR-relevant marketed products – are planning to, currently collecting or support the collection of surveillance data. More than half of the responding companies are planning to, or are currently engaged in, stewardship education activities, directly or collaboratively. This number increases to 70% for those companies with a marketed AMR-relevant product. However, it is broadly acknowledged that there is a considerable way to go, and the potential of vaccines and diagnostics is not yet fully explored.
Manufacturing and the environment: Alliance companies, particularly those that made bold commitments in the Roadmap, are taking action to reduce the potential impacts of antibiotics manufacturing on AMR. One third of the Alliance companies that produce antibiotics currently have a strategy, policy or plan in place to address the issue of the release of antibiotics in their own manufacturing effluent that may contribute to AMR. Three quarters of them anticipate the implementation of good practice methods to reduce environmental impact of manufacturing discharge by 2018, well ahead of the 2020 target. The report also features a newly drafted common framework for managing antibiotic discharge across company supply chains.
Progress report: https://www.amrindustryalliance.org/progress-report/
About the AMR Industry Alliance
The AMR Industry Alliance is a coalition of over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap and measures progress made in the fight against antimicrobial resistance.
About SustainAbility
SustainAbility is a consultancy and think tank enabling business to lead on the sustainability agenda.
Press contacts:
Morgane De Pol
IFPMA
m.depol@ifpma.org
+41 22 338 32 20
Kate O’Regan
Medicines for Europe
koregan@medicinesforeurope.com
+32 2 2392019
Marie Petit
BEAM Alliance
marie.petit@beam-alliance.eu
+33 6 50 01 15 33
Daniel Seaton
Biotechnology Innovation Organization (BIO)
dseaton@bio.org
+1.202.470.5207
Danielle M. Blake
AdvaMed
dblake@advamed.org
+1-202-434-7233
Today, organisations representing the life science industry in the EU and the UK have called for medicines to be a priority in phase 2 of the Article 50 negotiations.
Setting out their priorities in advance of the European Council taking place on 14-15th December in Brussels, the sector has sent a clear message that the regulation, trade and supply of medicines must be a priority for the second phase of negotiations.
Whilst being encouraged by the breakthrough in phase 1 of the negotiations so that the second phase can now begin, the sector states that focusing on the framework for transitional arrangements and future relations with the UK must be a priority for negotiators.
The organisations are of the opinion that the agreement of transitional arrangements after March 2019 will be critical in ensuring there is minimal disruption to patients receiving medicines after the UK leaves the EU. Such a period will be essential in allowing companies to make the necessary changes to marketing authorisations and to their supply chains and ensure patients experience no disruption to their access to medicines. As such, negotiators should include access to medicines and the implications of Brexit for patients across the EU in the second phase of negotiations and be agreed in both the future agreement and in transitional arrangements.
The publication of this joint policy paper shows that the integrated nature of the supply chains for medicines across Europe, alongside a shared regulatory framework, means that patients in both the UK and EU need an early agreement on the future of medicines in phase 2 of the negotiations.
Among several key priorities, the joint paper sets out the following:
Hubertus Cranz, Director General, Association of the European Self-Medication Industry (AESGP), stated:
“Self-care products are often the first choice when European citizens face a health issue. Phase two of the Brexit negotiations should make sure that the availability of non-prescription medicines and self-care medical devices is not put in danger. This requires an open minded, pragmatic approach concerning the transitional arrangements, but also for the long-term relationship between the UK and the future EU27. Concrete proposals have now been put on the table and we are confident that they will make a constructive contribution to the further negotiation process. The current EU regulatory network should be kept intact as much and as long as possible to avoid disruption to the supply of all kind of self-care products.”
Mike Thompson, CEO, Association of the British Pharmaceutical Industry (ABPI) said:
“As we look forward to confirmation of sufficient progress between the UK and the EU in Brexit talks, securing the best possible deal in phase two of the negotiations is now our focus.
“In phase two it is crucial that the regulation and supply of medicines for UK and EU patients is prioritised. A cooperation agreement between the UK and the EU on medicines is the best way to ensure that there is no disruption to 500 million patients receiving the medicines that they need.
“This agreement, alongside a single-step fixed-term transition period that allows companies to make any necessary changes to the supply chain, will be critical. Protecting public health in the UK and Europe must be a priority.”
Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA) and the British Biosimilars Association (BBA), said:
“We welcome the progress in Brexit talks but urge that in the second stage clarity is prioritised for the pharmaceutical sector. We have consistently stated that the existence of a single European regulatory system for medicines has generated considerable benefits for patients, the NHS and the industry. Both sides in the Brexit negotiations must find a way of maintaining these benefits in the interests of their citizens.”
Steve Bates, CEO, UK BioIndustry Association (BIA), said:
“The complex issues surrounding medicines regulation and supply chain need to be front and centre in the second phase of talks and industry needs a realistic transition period to ensure that the supply of lifesaving and life extending medicines to patients in the UK and across Europe is not affected. The life sciences industry stands ready to lend its expertise to the negotiating teams to ensure that there is no negative impact on public health and health security due to Brexit.”
Nathalie Moll, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA) said:
“The joint agreement announced last week between President Juncker and Prime Minister Theresa May provided a welcome breakthrough towards phase 2 of the negotiations. It is critical that this is confirmed by the European Council, and discussions move on as soon as possible to agreeing cooperation between the UK and the EU on the regulation, trade and supply of medicines. Health security must be a priority in this next stage of negotiations, alongside securing a transition period beyond March 2019. This is critical for patients in the UK and Europe.”
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
“Small and mid-sized companies are an indispensable factor for innovation in the healthcare and life sciences sector, and are catalysts of growth and competitiveness in Europe. To ensure that Europe and its patients continue to benefit from this, it is imperative that their capacity to operate is protected through the Brexit negotiations by minimising uncertainty and ensuring as much continuity as possible in the regulatory process between EU-27 and the UK.”
John Brennan, Secretary General, European Association for Bioindustries (EuropaBio), said:
“The simple facts are these: Many, many, European medicine approvals and European medicinal supply lines run through London and the UK. No matter how fast the Biotech industry and European drug approval authorities work together, we cannot succeed in adapting all drug approvals and all drug supply lines in time and by the 29th March. So the question to the negotiators is this: Do you want to prioritise medicines and allow an adequate transition, or do you want to risk interruption in the supply of life saving medicines to EU and UK patients?”
Adrian van den Hoven, Director General, Medicines for Europe said:
“We warmly welcome the important developments being achieved in the Brexit negotiating process. The recent compromise on the three key issues of phase one of the talks paves the way for discussions on the technical aspects of the future agreement, including public health.
In this regard, patient access to medicines should be of primary concern for negotiators as phase two of the talks begins. This encompasses a wide range of activities, including facilitating workable trade and customs mechanisms to ensure continued circulation of medicines between the UK and future EU27, as well as legal and regulatory provisions which enable companies to continue to supply European and British patients. This is particularly pertinent for the generic, biosimilar and value added medicines industry, which currently supplies the majority of medicines to patients in the European region.”
John Smith, Chief Executive, Proprietary Association of Great Britain (PAGB), comments:
“PAGB also welcomes that both parties have agreed the principles that goods on the market before withdrawal can continue to freely circulate on the markets of the UK and the Union with no need for product modifications or re-labelling. Thereafter, PAGB believes it is vital that appropriate mutual recognition agreements are put in place to allow over-the-counter and self-care products manufactured in the UK to continue to be exported to the EU and vice versa.”
The European Commission launched today additional translations of the Q&A paper “What I Need to Know about Biosimilar Medicines – Information for patients’’ making it available now in 23 official European languages, in order to provide patients with easy-to-understand information about biosimilar medicines. The Q&A was written to empower patients by providing answers to the most-frequently-asked questions on biosimilar medicines.
What are biosimilar medicines? How are they produced? How are they approved? Are they safe? – These questions and many more are addressed in this paper. Empowering patients to engage, discuss and participate in decisions on their treatment options is key to improving patient outcomes and contributing to the effective treatment of their individual condition(s).
In Europe, the introduction of biosimilar medicines brings competition, with the potential to improve patient access to biological medicines and contribute to healthcare system sustainability. Biosimilar medicines help treat many complex diseases, including cancer, diabetes, and autoimmune diseases (such as rheumatoid arthritis and inflammatory bowel disease). Biosimilar medicines have been used safely in the EU since 2006 as an alternative to reference medicines.
This Q&A is an initiative by the European Commission Directorate General for the Internal Market, Industry, Entrepreneurship and SMEs (DG Grow) on access to biosimilar medicines in Europe, in relation to the Corporate Responsibility Programme. This consensus information on biosimilar medicinal products was drafted by and for patients together with representatives of the European Medicines Agency, the European Commission and concerned stakeholders [the European Patients Forum (EPF), the European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA), the Standing Committee of European Doctors, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Association for BioIndustries (EuropaBio) and Medicines for Europe]. The Q&A was first launched in English in January 2017.
The above stakeholders would like to congratulate the European Commissions’ DG GROW and the European Medicines Agency on the developments during this programme. The Patient Q&A amongst other documents, such as “Biosimilars in the EU – Information guide for healthcare professionals” and “What you Need to Know about Biosimilar Medicinal Products – A Consensus Information Document”, have contributed significantly to the increased understanding and acceptance of biosimilar medicines.
The Standing Committee of European Doctors (CPME) represents national medical associations across Europe. We are committed to contributing the medical profession’s point of view to EU institutions and European policy-making through pro-active cooperation on a wide range of health and healthcare related issues.
For more information please contact:
Miriam Beatrice Vita D’Ambrosio, Communication and Project Officer
Email: miriam.dambrosio@cpme.eu / Telephone: +32 2 738 03 12
EPF currently represents 74 members, which are national coalitions of patient’ organisations and disease-specific patient organisations working at European level. EPF reflects the voice of an estimated 150 million patients affected by various chronic diseases throughout Europe.
EPF’s vision is that all patients with chronic and/or lifelong conditions in the EU have access to high quality, patient-centred equitable health and social care.
The EPF strategic goals focus on areas such as health literacy, healthcare design and delivery, patient involvement, patient empowerment, sustainable patients’ organisations and non-discrimination.
For more information please contact:
Sara Gayarre, Communications Assistant
Email: sara.gayarre@eu-patient.eu / Telephone: +32 2 274 08 64
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world. To learn more about EFPIA, visit: www.efpia.eu
For more information please contact:
Faraz Kermani, Communications Manager – External Affairs
Email: communications@efpia.eu / Telephone: +32 2 626 25 55
EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. EuropaBio represents 79 corporate and associate members and bio-regions, and 17 national biotechnology associations in turn representing over 1800 biotech SMEs. Read more about our work at www.europabio.org.
For more information please contact:
Cosmin Popa, Communications and National Associations Manager
Email: c.popa@europabio.org / Telephone: +32 2 739 11 73
Medicines for Europe represents the generic, biosimilar and value added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members employ 160,000 people at over 350 manufacturing and R&D sites in Europe, and invest up to 17% of their turnover in medical innovation. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information please follow us at www.medicinesforeurope.com and on Twitter @medicinesforEU.
The Biosimilar Medicines Group is a sector group of Medicines for Europe and represents the leading companies developing, manufacturing and marketing biosimilar medicines across Europe. Our members bring competition to the biologic medicines market, thereby increasing access to highly innovative medical treatments for patients in Europe and around the world, and supporting the sustainability of the European healthcare systems.
For more information please contact:
Andrea Bedorin, Communications Manager
Email: abedorin@medicinesforeurope.com / Telephone: +32 2 239 20 14
The associations representing the European and British life science industry (AESGP, EFPIA, EuropaBio, EUCOPE, Medicines for Europe, ABPI, BGMA, BIA, PAGB) have today underlined the importance of securing cooperation between the UK and EU on medicines regulation.
Whilst we respect the phased approach of negotiations, we urge progress to be made in the negotiations as soon as possible.
We urge Brexit negotiators on both sides to agree on a transition period that adequately reflects the time needed by companies, as well as all relevant authorities at EU and national level to adapt to changes in view of the UK exiting the EU. The transition period should provide for continued EU-UK partnership on the regulation and supply of medicines, to avoid supply disruption while moving forward towards a future cooperation agreement between the EU and the UK.
Our industry is highly integrated across Europe, and regulated under EU law through a sophisticated system of legal and regulatory arrangements involving EU Institutions, Member States and national competent authorities.
For our sector Brexit represents a challenge in several areas, notably regulatory procedures, quality testing of medicines, supply chain, trade, and intellectual property. For example, medicines companies may need to submit applications for the transfer of marketing authorisation for many products, move batch release sites and duplicate quality testing for products or move personnel into either jurisdiction. This will take a significant amount of time and will result in capacity issues which cannot be resolved before March 2019.
Clarity and certainty are needed as early as possible to enable our industry to make the necessary changes and to transition smoothly into the new framework. This is key to ensure that there is no disruption in the supply of medicines tor patients after March 20191.
Even in the context of the Brexit negotiations where all sectors are looking for clarity on the future, it’s important to recognise that medicines are different. Our goal is ensuring that patients across Europe and the UK are able to continue to access safe and effective medicines through Brexit and beyond, and to ensure that there is no adverse impact on public health. This goal should be front of mind for both the EU and UK negotiating teams.
The 1st Value Added Medicines conference organised by the Value Added Medicines Group, a sector group of Medicines for Europe, which took place today, 22nd November, gathered a wide range of experts in the healthcare community to raise awareness and foster debate on a common approach to present solutions for patient-centric innovation and better patient access to these medicines.
Health delivery models in Europe are being challenged by an ageing, rising patient population and current healthcare economic constraints, threatening the sustainability of Europe’s healthcare systems. There is a need for a new value proposition for patients, healthcare professionals and healthcare systems, especially to address clinical (adherence, quality of life) and economic inefficiencies. According to IQVIA, patient non-adherence is undoubtedly the biggest source of these, representing 57% of all inefficiency costs[1], and limiting the ability for patients to best manage their condition. Value added medicines can address these challenges by improving patient adherence and quality-of-life issues, while addressing medicine-related healthcare inefficiencies and improving healthcare provision and organisation thereby contributing to the sustainability of healthcare systems.
Marc-Alexander Mahl, Medicines for Europe President, highlighted that ‘We have a responsibility to look at European healthcare systems and see how we can contribute value to patients, healthcare professionals and society. Value added medicines deliver patient-centric gains. To continue the development of this sustainable innovation, there is a need for a favourable environment, where the development efforts can be reasonably recognised, and the access to value added medicines is well integrated in healthcare systems.’
Umberto Comberiati, Chair of the Value Added Medicines Group at Medicines for Europe, commented: “The wide range of stakeholders present at today’s conference has confirmed the wide interest surrounding value added medicines. We actively engage all the stakeholders from policymakers to patients, industry and payers to see how together we can address patients’ needs through the relevant outcomes that value added medicines can deliver. These benefits need to be more widely recognised and incentivised to promote the development of value added medicines in Europe. Pricing, HTA and market access pathways should be adapted to fully appreciate the benefits of this patient centric innovation”.
[1] IQVIA European Thought Leadership; IQVIA Institute 2012 “Responsible use of Medicine”
Medicines for Europe is very glad to see the Council of the European Union reach a decision today, to relocate the European Medicines Agency (EMA) to Amsterdam. This is an important milestone in the Brexit process, bringing us from a point of uncertainty to clarity concerning the future of the EMA and the important work it carries out for public health.
Of course, the real work starts now. Looking to the next steps in the process, we hope for a well elaborated relocation plan, which will provide certainty for both EMA staff and for the continuity of the work of the agency. In particular, we hope to see key EMA projects and coordination run smoothly, to avoid disruptions in pharmaceutical regulatory activities – ranging from the approval for marketing to the post-marketing surveillance of medicines. In this regard, we particularly look forward to the EMA continuing to implement important information technology projects like ISO-IDMP, and to lead the way on biosimilar medicines, both in the EU and globally. The pioneering work of the EMA on biosimilars in Europe has ensured that patient access to treatment has increased, and to let this, as well as other projects of the EMA, slip during relocation would have serious negative consequences.
Our primary concern is that now this decision has been taken, we as healthcare stakeholders now focus on continuing this work, which of course is paramount to ensuring supply and access to medicines for patients. We look forward to continuing this important work in Amsterdam, the new home of the EMA.
On Thursday 12 October, the Directorate-general for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) launched a public consultation on the Supplementary Protection Certificate (SPC) Manufacturing Waiver and the Bolar exemption. Medicines for Europe calls for a swift introduction of the SPC manufacturing waiver in EU legislation and for a wide definition of Bolar. These measures would create a more competitive industry as demonstrated in the CRA study sponsored by the European Commission “Assessing the economic impacts of changing exemption provisions during patent and SPC protection in Europe”. According to the report, the SPC manufacturing waiver would:
The SPC compensates originator drug manufacturers for regulatory approval delays by extending their monopoly for up to 5 years after patent expiry. Whilst our industry does not challenge the principle of compensation for delays, the application of the SPC forces generic and biosimilar manufacturers to manufacture outside of Europe for export to countries without SPCs or whose SPC expires earlier than in Europe. With the SPC manufacturing waiver European medicine manufacturers will be able to re-invest in high skill jobs in Europe. To improve access to life saving medicines for patients, the SPC manufacturing waiver complements the Bolar provision and enable European manufacturers to bring competition at the date of SPC expiry and without unnecessary delays.
As proposed by the European Commission and confirmed in several studies, the SPC manufacturing waiver will not affect originator drug manufacturers as they will continue to benefit from the longest period of monopoly protection globally for most drugs.
Adrian van den Hoven, Director General at Medicines for Europe commented that “the CRA study shows the huge benefits that the SPC Manufacturing Waiver and Bolar harmonisation offer Europe in terms of jobs, manufacturing and a lower overall medicines bill. The Commission must now legislate to make this a reality.”
Medicines for Europe Communications:
Andrea Bedorin abedorin@medicinesforeurope.com
Definitions
The newly elected President of Medicines for Europe – Marc-Alexander Mahl – launched the “Access to Medicines: Better Care for More Patients” campaign which calls on health ministers to fully embrace generic, biosimilar and value-added medicines to improve the sustainability of healthcare systems across Europe.
Dr. Mahl takes over the Presidency of Medicines for Europe for 2 years. As Executive Vice President Business Unit Generic Drugs at Fresenius Kabi, Marc-Alexander Mahl chaired the Hospital Sector at Medicines for Europe. A physician by training, he completed his specialization in transfusion medicine and blood banking in 2001, the year he also joined Fresenius Kabi. He also holds an Executive MBA from INSEAD.
Today, in Warsaw, Marc-Alexander Mahl explained: “European healthcare is under financial constraint with many patients struggling to get access to treatments. The increasing overall cost of healthcare will force policy-makers to make difficult and unpopular choices about how best to allocate resources. Yet there is a very simple and obvious way to ensure access while managing healthcare budgets: to promote generic, biosimilar and value added medicines use by patients, medical professionals and pharmacists.” The new campaign will provide compelling data and proposals to help policy-makers and stakeholders improve access to medicines. In particular, the campaign will help policy-makers encourage competition in complex, specialty medicine markets where there are tremendous opportunities to increase access, spend resources more efficiently and improve overall care for patients.
Value added medicines represent a major opportunity to improve patients’ quality of life, health outcomes or adherence, and to address a number of medicine-related healthcare inefficiencies, improving healthcare provision and organisation while contributing to the sustainability of healthcare systems.
To ensure access to value added medicines for patients, the Value Added Medicines Group, a sector group of Medicines for Europe, will participate in the ISPOR 20th Annual European Congress on an Issue Panel entitled “Value Added Medicines: Time To Adjust The Health Technology Assessment Decision Frameworks?”.
Moderated by Professor Michael Drummond (Professor of Health Economics at the Univerity of York), the panellists (Professor Mondher Toumi from the Public Health Department of Aix-Marseille University, Professor Ulf Persson from the Swedish Institute of Health Economics and Luigi Burgio – Head of Market Access Teva Italy and Chairman of the HTA Working Group at Medicines for Europe) will debate current challenges for capturing the benefits of value added medicines as well as key recommendations to integrate and recognise patient-centric innovation in HTA decision frameworks.
Umberto Comberiati, the Chairman of the Value Added Medicines Group,: “The time has come to explore new areas to deliver better health and access for patients, tapping into a sustainable source of patient-centric innovation. Value added medicines are an opportunity to deliver benefits to patients, payers and healthcare systems. However, there is a challenge to ensure that benefits can be appropriately assessed via HTA decision frameworks. The ISPOR Issue Panel will allow an informed debate among experts, industry and stakeholders.”
Medicines for Europe invites you to join the ISPOR European Congress in Glasgow and please follow us on Twitter and LinkedIn to know more about how European patients can better benefit from value added medicines. More information on the Issue Panel and the challenges and recommendations on adjusted HTA decision frameworks for value added medicines can be found here.